TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Core Insights - TG Therapeutics, Inc. (TGTX) shares have increased by 29.5% over the past three months, contrasting with an 11.2% decline in the industry [1] - The company's primary revenue source is from its marketed drug Briumvi, which has exceeded sales expectations in 2024 [1][2] Group 1: Briumvi Performance - Briumvi's net product sales reached $313.7 million in 2024, a significant increase from$92 million in 2023 [2] - The strong sales performance of Briumvi is a key factor driving the stock's increase [2] - TG Therapeutics anticipates worldwide revenues of approximately $540 million in 2025, with nearly$525 million expected from Briumvi sales in the U.S. [3] Group 2: Patent and Development Updates - The company has secured three additional patents for Briumvi, extending its patent protection until 2042, which will help safeguard against generic competition [3] - TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi, with a phase I study already initiated for patients with relapsing forms of multiple sclerosis [4] Group 3: Pipeline and Future Prospects - TG Therapeutics entered a licensing agreement with Precision BioSciences for the allogeneic CD19 CAR T therapy, azercabtagene zapreleucel, aimed at treating certain autoimmune disorders [7] - The FDA has cleared the investigational new drug application for azer-cel for progressive forms of multiple sclerosis, with participant enrollment in the phase I study expected to begin soon [7][8] - The combination of strong Briumvi adoption and positive pipeline developments is expected to continue driving TGTX stock performance in 2025 [8]